0000905148-24-000061.txt : 20240103 0000905148-24-000061.hdr.sgml : 20240103 20240103192523 ACCESSION NUMBER: 0000905148-24-000061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reinhart Harald CENTRAL INDEX KEY: 0001835824 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 24509167 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR STREET 2: PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 form4.xml X0508 4 2024-01-01 0001704292 Zai Lab Ltd ZLAB 0001835824 Reinhart Harald C/O ZAI LAB LIMITED 314 MAIN STREET, 4TH FLOOR, SUITE 100 CAMBRIDGE MA 02142 true See Remarks false American Depositary Shares 2024-01-01 4 M 0 17548 A 50863 D American Depositary Shares 2024-01-03 4 S 0 4803 26.122 D 46060 D Performance-Based Share Units 2024-01-01 4 A 0 17548 0 A American Depositary Shares 17548 17548 D Performance-Based Share Units 2024-01-01 4 M 0 17548 0 D American Depositary Shares 17548 0 D Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. ADSs acquired on vesting of performance-based share units (PSUs). Each ADS represents ten Ordinary Shares of the issuer. Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer. These ADSs were sold automatically to cover taxes upon vesting of PSUs. The reporting person was granted PSUs on December 1, 2021 that vest based on the satisfaction of specified performance criteria between December 1, 2021 and December 31, 2025. On January 1, 2024, the performance-based vesting conditions were confirmed for PSUs representing 17,548 ADSs. President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases /s/ Bruce Blefeld, Attorney-in-Fact 2024-01-03